Dazdotuftide, which exerts dual inhibition on TLR/NF-κB signaling and NRP-1/VEGF signaling while promoting macrophage polarization toward the anti-inflammatory M2 phenotype, has been proposed as a potential treatment for DR and both forms of AMD (71). The gene discussed is NRP1; the disease is age-related macular degeneration.